Pharmaceutical syrup formulation or suspension

Abstract

A stable pharmaceutical formulation or suspension has a pharmaceutical active agent, agave, and a dilutant. The formulation or suspension has viscosity suitable for drinking.

1 . A pharmaceutical syrup formulation for oral administration comprising: a pharmaceutical active agent, agave syrup, and a dilutant, wherein the syrup formulation has a viscosity of less than 1500 centipoise at about 22 degrees. 
     
     
         2 . The pharmaceutical syrup formulation of  claim 1 , the syrup formulation viscosity of less than 1000 centipoise at about 22 degrees. 
     
     
         3 . The pharmaceutical syrup formulation of  claim 1 , the syrup formulation viscosity of less than 750 centipoise at about 22 degrees. 
     
     
         4 . The pharmaceutical syrup formulation of  claim 1 , the syrup formulation viscosity of less than 600 centipoise at about 22 degrees. 
     
     
         5 . The pharmaceutical syrup formulation of  claim 1 , wherein the pharmaceutical active agent is antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, mucolytics, analgesics, antipyretics, anti-inflammatory agents, local anesthetics, and mixtures thereof. 
     
     
         6 . A stable pharmaceutical syrup formulation for oral administration comprising: a pharmaceutical active agent; agave syrup; acidic preservative; a sweetening agent; a flavoring agent, and a dilutant, wherein the syrup formulation has a viscosity of less than 1500 centipoise at about 22 degrees. 
     
     
         7 . The pharmaceutical syrup formulation of  claim 6 , the pharmaceutical active agent is less than 2% of the formulation by weight. 
     
     
         8 . The pharmaceutical syrup formulation of  claim 6 , the dilutant is less than 5% of the formulation by weight. 
     
     
         9 . The pharmaceutical syrup formulation of  claim 6 , the agave syrup is less than 50% of the formulation by weight. 
     
     
         10 . The pharmaceutical syrup formulation of  claim 6 , the agave syrup is less than 90% of the formulation by weight. 
     
     
         11 . The pharmaceutical syrup formulation of  claim 6 , the dilutant water. 
     
     
         12 . The pharmaceutical syrup formulation of  claim 6 , wherein the pharmaceutical active agent is antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, mucolytics, analgesics, antipyretics, anti-inflammatory agents, local anesthetics, and mixtures thereof. 
     
     
         13 . The pharmaceutical syrup formulation of  claim 6 , wherein the pharmaceutical active agent selected from the group consisting of dextromethorphan, guaifenesin, pseudoephedrine, acetaminophen, phenylephrine and combinations thereof. 
     
     
         14 . The pharmaceutical syrup formulation of  claim 6 , wherein the acidic preservative comprises citric acid. 
     
     
         15 . The pharmaceutical syrup formulation of  claim 6 , wherein the composition is a medicinal preparation formulated as a syrup; wherein the composition has a viscosity from about 1500 centipoise to about 400 centipoise at about 22 degrees. 
     
     
         16 . The pharmaceutical syrup formulation of  claim 6 , wherein the formulation is orally administered for veterinary and human use. 
     
     
         17 . The pharmaceutical syrup formulation of  claim 6 , wherein the pharmaceutical active is acetaminophen. 
     
     
         18 . The pharmaceutical syrup formulation of  claim 6 , wherein the flavoring agent is a bitter-blocking ingredient. 
     
     
         19 . A stable, palatable pharmaceutical syrup formulation for oral administration consisting essentially of a pharmaceutical active agent; agave syrup; acidic preservative; a sweetening agent; a flavoring agent, and a dilutant, wherein the syrup formulation has a viscosity of less than 1000 centipoise at about 22 degrees. 
     
     
         20 . The formulation of  claim 19 , wherein the pharmaceutical active agent is hydrophilic.